This study aimed to evaluate racial/ethnic differences in lung cancer incidence and mortality in the Women's Health Initiative Study, a longitudinal prospective cohort evaluation of postmenopausal women recruited from 40 clinical centers.
Multidisciplinary tumor board meetings are common in cancer care, but limited evidence is available about their benefits. We assessed the associations of tumor board participation and structure with care delivery and patient outcomes.
CT lung cancer screening turns out to be like many new medical technologies: It improves health but is quite expensive. Moreover, it needs implementation that targets those most likely to benefit and provides them the care they need efficiently.
CT screening reduced death from lung cancer by 20% during a 6 year trial among heavy smokers age 50-74; the cost was about $81,000/QALY gained. If screening is extended to not-so-heavy smokers, its value falls dramatically, and radiation risks may outweigh screening gains.
Both practice environment and patient clinical and demographic characteristics are associated with cancer clinical trial enrollment; simultaneous intervention may be required when trying to increase enrollment rates.
In a Northern Italian population, the absolute risk of lung cancer among never smokers is higher in women than men but among smokers is lower in women than men. Lexpit regression is a novel approach to additive-multiplicative risk modeling that can contribute to clearer interpretation of population-based case–control studies.
Nurses play a key role in educating cancer patients and their caregivers on how to effectively cope with and manage cancer. African American caregivers may benefit from interventions tailored to their specific caregiving experience.
U.S. patients' reports and ratings of cancer care differed significantly by race, language, and health status. Asian/Pacific Islanders, Chinese speakers, and those in worse health reported worse interpersonal care, such as poor communication.
Older patients receiving chemotherapy for advanced-stage, non-small-cell lung cancer had fewer pretherapy adverse events than younger patients and were less likely to receive platinum-based regimens. But they had more adverse events during chemotherapy.